Modulation of Apoptosis with Cytokines in B-Cell Chronic Lymphocytic Leukaemia

References

• Williams G T, Smith C A, McCarthy N J, Grimes E A. Apoptosis: final control point in cell biology. Trends in Cell Biol 1992; 2: 263–267
   PubMedGoogle Scholar
• McCarthy N J, Smith C A, Williams G T. Apoptosis in the development of the immune system. Growth factors clonal selection and bcl-2. Cancer Metastasis Rev 1992; 11: 157–178
   PubMed Web of Science ®Google Scholar
• Lockshin R A, Beaulaton J. Programmed cell death. Life Sci 1974; 15: 1549–1565
   PubMed Web of Science ®Google Scholar
• Wyllie A H, Kerr J F. R, Currie A R. Cell death: The significance of apoptosis. Int. Rev. Cytol 1980; 68: 251–300
   PubMedGoogle Scholar
• Wyllie A H, Morris R G, Smith A L, Dunlop D. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol 1986; 142: 67–77
   Web of Science ®Google Scholar
• Wyllie A H, Morris R G. Hormone-induced cell death. Purification and properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am. J. Pathol 1982; 109: 78–87
   PubMed Web of Science ®Google Scholar
• Smith C A, Williams G T, Kingston R, Jenkinson E J, Owen J J. T. Antibodies to CD3/T cell receptor complex induce cell death by apoptosis in immature T cell thymic cultures. Nature 1989; 337: 181–184
   PubMed Web of Science ®Google Scholar
• Dexter T M, Hayworth C M, Spooner E, Ponting I L. O. The role of growth factors in self renewal and differentiation of stem cells. Philos. Trans. R. Soc. Lond. Biol 1990; 327: 85–98
   PubMed Web of Science ®Google Scholar
• Duke R C, Cohen I J. IL2 addiction: withdrawal of growth factor activates a suicidal programme in dependent T cells. Lymphokine Res 1986; 5: 289–299
   PubMedGoogle Scholar
• Williams G T, Smith C A, Spooner E, Dexter T M, Taylor D R. Haematopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 346: 76–79
   PubMed Web of Science ®Google Scholar
• Hewish D R, Burgoyne L A. Chromatin structure. The digestion of chromatin at regularly spaced sites by a nuclear deoxyribonuclease. Biochem. Biophys. Res. Commun 1973; 52: 504–510
   PubMed Web of Science ®Google Scholar
• Cohen J J, Duke R C. Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol 1984; 132: 38–42
   PubMed Web of Science ®Google Scholar
• Cohen J J. Programmed cell death. Adv. Immunol 1991; 50: 55–85
   PubMed Web of Science ®Google Scholar
• Baffy G, Miyashita T, Williamson J R, Reed J C. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3 dependent haematopoietic cell line is associated with repar-titioning of intracellular calcium and is blocked by enforced bcl-2 oncoprotein production. J. Biol. Chem 1993; 268: 6511–6519
   PubMed Web of Science ®Google Scholar
• Dowd D R, MacDonald P N, Komm B S, Haussler M R, Miesfeld R. Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J. Biol. Chem 1991; 266: 18423–18426
   PubMed Web of Science ®Google Scholar
• Story M D, Stephens L D, Tomasovic S P, Meyn R E. A role for calcium in regulating apoptosis in rat thymocytes irradiated in vitro. Int. J. Radiat. Biol 1992; 61: 243–251
   PubMed Web of Science ®Google Scholar
• McConkey D J, Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol 1994; 4: 370–375
   PubMedGoogle Scholar
• Iwata M, Iseki R, Tozawa Y, Ohoka Y. Involvement of protein kinase C-e in glucocorticoid-induced apoptosis in thymocytes. Int. Immunol 1994; 6: 431–438
   PubMed Web of Science ®Google Scholar
• Kroemer G, Martiez A C. Pharmacological inhibition of programmed lymphocyte death. Immunol. Today 1994; 15: 235–242
   PubMedGoogle Scholar
• Knox K A, Gordon J. Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B cells from apoptosis. Eur. J. Immunol 1993; 23: 2578–2584
   PubMed Web of Science ®Google Scholar
• Bergamaschi G, Rosti V, Danova M, Ponchio L, Lucotti C, Cazzola M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukaemic cell lines. Leukemia 1993; 7: 2012–2018
   PubMed Web of Science ®Google Scholar
• Buttke T M, Sandstrom P A. Oxidative stress as a mediator of apoptosis. Immunol. Today 1994; 15: 7–10
   PubMedGoogle Scholar
• Schwartz L M, Osborne B A. Programmed cell death, apoptosis and killer genes. Immunol. Today 1993; 14: 582–590
   PubMedGoogle Scholar
• Harrington E A, Fanidi A, Evan G I. Oncogenes and cell death. Curr. Opin. Genet. Dev 1994; 4: 120–129
   PubMed Web of Science ®Google Scholar
• Evan G I, Wyllie A H, Gilbert C S, Littlewood T D, Land H, Brooks M, Waters C M, Penn L Z, Hancock D C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119–128
   PubMed Web of Science ®Google Scholar
• Vaux D L, Cory S, Adams J M. Bcl-2 gene promotes haematopoietic cell survival and co-operates with c-myc to immortalise pre-B cells. Nature 1988; 335: 440–442
   PubMed Web of Science ®Google Scholar
• Shi Y, Glynn J M, Guilbert L J, Cotter T G, Bissonette R P, Green D R. Role of c-myc in activation-induced apoptotic cell death in T-cell hybridomas. Science 1992; 257: 211–214
   Web of Science ®Google Scholar
• Askew D S, Ashmun R A, Simmons B C, Cleveland J L. Constitutive c-myc expression in an IL3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915–1922
   PubMed Web of Science ®Google Scholar
• Bissonette R P, Echeverri R, Mahboubi A, Green D R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552–554
   PubMed Web of Science ®Google Scholar
• Fanidi A, Harrington E A, Evan G I. Cooperative interaction between c-myc and bcl-2 proto-oncogene. Nature 1992; 359: 554–556
   PubMed Web of Science ®Google Scholar
• Itoh N, Yonehara S, Ishii A I, Yonehara M, Mizushima S.-I, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243
   PubMed Web of Science ®Google Scholar
• Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth B C, Ponstingl H, Krammer P M. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem 1992; 267: 10709–10715
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan C I, Copeland N G, Jenkins N A, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317
   PubMed Web of Science ®Google Scholar
• Tsuijimoto Y, Finger L R, Yunis J, Nowell P C, Croce C M. Cloning of a chromosomal breakpoint of neoplastic B cells within the t(14; 18) chromosome translocation. Science 1984; 226: 1097–1099
   PubMed Web of Science ®Google Scholar
• Chen-Levy Z, Nourse J, Cleary M L. The bcl-2 candidate proto-oncogene product is a 24 kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t (14; 18) translocation. Mol. Cell. Biol 1986; 9: 701–710
   Web of Science ®Google Scholar
• McDonnell T J, Deane N, Piatt F M, Nunez G, Jaegar U, McKearn J P, Korsmeyer S J. bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79–88
   PubMed Web of Science ®Google Scholar
• McDonnell T J, Nunez G, Piatt F M, Hockenbery D, London L, McKearn J P, Korsmeyer S J. Deregulated bcl-2 immunoglobulin transgene expands a resting but responsive immunoglobulin M- and D-expressing B cell population. Mol. Cell. Biol 1990; 10: 1901–1907
   PubMed Web of Science ®Google Scholar
• Sentman C L, Shutter J R, Hockenbery D, Kanagawa O, Korsmeyer S J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879–888
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, Schreiber R D, Korsmeyer S J. Bcl-2 is an inner mitochondria membrane molecule that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Nunez G, London L, Hockenbery D, Alexander M, McKearn J P, Korsmeyer S J. De-regulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived haematopoietic cell lines. J. Immunol 1990; 144: 3602–3610
   PubMed Web of Science ®Google Scholar
• Borzillo G V, Endo K, Tsujimoto Y. Bcl-2 confers growth and survival advantage to interleukin-7-dependent early pre-B cells which become factor independent by a multistep process in culture. Oncogene 1992; 7: 869–876
   PubMed Web of Science ®Google Scholar
• Garcia I, Martinou I, Tsujimoto Y, Martinou J C. Prevention of programmed cell death of sympathetic neurones by the bcl-2 proto-oncogene. Science 1992; 258: 302–304
   PubMed Web of Science ®Google Scholar
• Strasser A, Harris A W, Bath M L, Cory S. Novel primitive lymphoid tumours induced in trangenic mice by co-operation of myc and bcl-2. Nature 1990; 348: 331–333
   PubMed Web of Science ®Google Scholar
• Nunez G, Seto M, Seremetis S, Ferrero D, Grignani F, Korsmeyer S J, Dalla-Favera R. Growth- and tumour-promoting effects of deregulated bcl-2 in human B-lym-phoblastoid cells. Proc. Natl. Acad. Sci. USA 1989; 86: 4589–4593
   PubMed Web of Science ®Google Scholar
• McDonnell T J, Korsmeyer S J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18). Nature 1991; 349: 254–256
   PubMed Web of Science ®Google Scholar
• Vaux D L, Aguila H L, Weissman I. Bcl-2 prevents death of factor deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol 1992; 4: 821–824
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Reed J C, De Valck D, Grooten J, Miyashita T, Tanaka S, Beyaert R, Van Roy F., Fiers W. Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumour necrosis factor-mediated cytotoxicity. Oncogene 1993; 8: 1075–1081
   PubMed Web of Science ®Google Scholar
• Dameshek W. Chronic lymphocytic leukaemia—An accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566–572
   PubMed Web of Science ®Google Scholar
• Foon K A, Rai K R, Gale R P. Chronic lymphocytic leukaemia: New insights into biology and therapy. Ann. Intern. Med 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Nilsson K. The control of growth and differentiation in chronic lymphocytic leukaemia (B-CLL) cells. In Chronic Lymphocytic Leukaemia Scientific Advances and Clinical Developments, D B Cheson. M. Dekker Inc, London 1992; 33
   Google Scholar
• Geisler C H, Larsen J K, Hansen N E, Hansen M M, Christensen B E, Lund B, Nielson H, Plesner T, Thorling K, Andersen E, Andersen P K. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukaemia. Blood 1991; 78: 1745–1802
   Web of Science ®Google Scholar
• Caligaris-Cuppio F, Janossy G. Surface markers in chronic lymphocytic leukaemia of B-cell type. Sem. Hematol 1985; 22: 1–12
   PubMed Web of Science ®Google Scholar
• Andreeff M, Darzynkiewicz Z, Sharpless T K, Clarkson B D, Melamed M R. Discrimination of human leukaemia sub-types by flow cytometric analysis of cellular DNA and RNA. Blood 1980; 55: 282–293
   PubMed Web of Science ®Google Scholar
• Rickinson A B, Finerty S, Epstein M A. Interaction of Epstein-Barr virus in leukaemic B-cell in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemia cells. Clin. Exp. Immunol 1982; 50: 347–354
   PubMed Web of Science ®Google Scholar
• Karray S, Merle-Beral H, Vazquez A, Gerard A, Debre P, Galanaud P. Functional heterogeneity of B-CLL lymphocytes: Dissociated responsiveness to growth factor and distinct requirements for a first activation signal. Blood 1987; 70: 1105–1110
   PubMed Web of Science ®Google Scholar
• Touw I, Dorssers L, Lowenberg B. The proliferative response of B-cell chronic lymphocytic leukaemia to interleukin 2: functional characterisation of the interleukin 2 membrane receptors. Blood 1987; 69: 1667–1673
   PubMed Web of Science ®Google Scholar
• Karray S, DeFrance T, Merle-Beral H, Banchereau J, Debre P, Galanaud P. Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B-cells. J. Exp. Med 1988; 168: 85–94
   PubMed Web of Science ®Google Scholar
• Morbets R, Hoogerbrugge H, van Agthoven T, Lowenberg B, Touw I. Proliferative response of highly purified B chronic lymphocytic leukaemia cells in serum free culture to interleukin 2 and tumour necrosis factors alpha and beta. Leukemia Res 1989; 13: 973–980
   PubMed Web of Science ®Google Scholar
• Martinez O M, Gibbons R S, Garovay M R, Aronson F R. Interleukin 4 inhibits interleukin-2 receptor expression and interleukin 2 dependent proliferation of human T-cells. J. Immunol 1990; 144: 2211–2215
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Copplestone J A, Prentice A G. Effect of interleukins on the proliferation and survival of B-chronic lymphocytic leukaemia cells (B-CLL). J. Clin. Pathol 1995; 48: 482–487
   PubMed Web of Science ®Google Scholar
• Alvarez-Mon M, de la Hera A, Gaspar M L, Orfao A, Casas J, Jorda J, Durantez A. Proliferation of B-cells from chronic lymphocytic leukaemia is selectively promoted by B-cell growth factor. Acta Haematol 1989; 81: 91–97
   PubMed Web of Science ®Google Scholar
• Digel W, Stefanic M, Schoniger W, Buck C, Ragharachar A, Frickhoften N, Heimpel H, Rorzsolt F. Tumour necrosis factor induces proliferation of neoplastic B-cells from chronic lymphocytic leukaemia. Blood 1989; 73: 1241–1246
   Web of Science ®Google Scholar
• Van Kooten C, Rensink K. H. J. A. M., Aarden L A, Van Oers M H. J. Interleukin 4 inhibits both paracrine and autocrine TNF—induced proliferation of B-chronic lymphocytic leukaemia cells. Blood 1992; 80: 1299–1306
   PubMed Web of Science ®Google Scholar
• Karray S, Delfraissy J.-F, Merle-Beral H, Wallon C, Debre P, Galanaud P. Positive effects of interferon-α on B-cell type chronic lymphocytic leukaemia proliferative response. J. Immunol 1988; 140: 774–778
   PubMed Web of Science ®Google Scholar
• Ostlund L, Biberfeld P, Robert K.-H, Christensson B, Einhorn S. Induction of proliferation and blast transformation by interferon in human malignant and non malignant lymph node B cells. Blood 1989; 73: 2171–2181
   PubMed Web of Science ®Google Scholar
• Hoffbrand A V, Panayiotidis P, Reittie J, Ganeshaguru K. Autocrine and paracrine growth loops in chronic lymphocytic leukaemia. Sem. Hematol 1993; 30: 306–317
   PubMed Web of Science ®Google Scholar
• Aguilar-Santelises M, Magnusson R, Svenson S B, Loftenius A, Andersson B, Mellstedt H, Jondal M. Expression of interleukin-1α, interleukin-1β and interleukin-6 in chronic lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin. Exp. Immunol 1991; 84: 422–428
   PubMed Web of Science ®Google Scholar
• Plate J M. D, Knospe W H, Harris J E, Gregory S A. Normal and aberrant expression of cytokines in neoplastic cells from chronic lymphocytic leukaemias. Hum. Immunol 1993; 36: 249–258
   PubMed Web of Science ®Google Scholar
• Lahat N, Aghai E, Maroun B, Kinarty A, Quitt M, Froom P. Increased spontaneous secretion of IL-6 from B-cells of patients with B chronic lymphocytic leukaemia (B-CLL) and autoimmunity. Clin. Exp. Immunol 1991; 85: 302–306
   PubMed Web of Science ®Google Scholar
• Cordingley F T, Bianchi F, Hoffbrand A V, Reittie J, Heslop H E, Vyakarnam A, Turner M, Brenner M K. Tumour necrosis factor as an autocrine growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969–971
   PubMed Web of Science ®Google Scholar
• Harm T, Kusminksky G, Bassous L, Berrebi A. Tumour necrosis factor production in B cell chronic lymphocytic leukaemia. Leukaemia and Lymphoma 1991; 4: 117–121
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambella R, Agostini C, Siviero F, Adami F, Marcolongo R, Raimondi R, Chisesi T, Pizzolo G, Semenzato G. Expression and functional role of tumour necrosis factor receptors on leukaemic cells from patients with type B chronic lymphocytic leukaemia. Blood 1993; 81: 752–758
   PubMed Web of Science ®Google Scholar
• Collins R J, Verschuer L A, Harmon B V, Prentice R L, Pope J H, Kerr J F. R. Spontaneous programmed death (apoptosis) of B chronic lymphocytic leukaemia cells following their culture. in vitro. Br. J. Haematol 1989; 71: 343–350
   PubMed Web of Science ®Google Scholar
• McConkey D J, Aguilar-Santelises M, Hartcell P, Eriksson I, Mellstedt H, Orrenius S, Jondal M. Induction of DNA fragmentation in chronic B-lymphocytic leukaemia cells. J. Immunol 1991; 146: 1072–1076
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Ganeshaguru K, Jabbar S A. B, Hoffbrand A V. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells. in vitro. Br. J. Haematol 1993; 85: 439–445
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Craig V A, Copplestone J A, Hamon M D, Prentice A G. Interleukin-5 (IL5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukaemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4. Blood 1994; 84: 2297–2304
   PubMed Web of Science ®Google Scholar
• Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 1991; 25: 70–72
   Web of Science ®Google Scholar
• Shena M, Larsson L G, Gattardi D, Gaidano G L, Garlsson M, Nilsson K, Caligaris-Cappio F. Growth and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukaemia cells. Blood 1992; 79: 2981–2889
   PubMed Web of Science ®Google Scholar
• Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer P H. Co-regulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B-cells and in follicle centre and mediastinal B-cell lymphomas. Blood 1993; 81: 2067–2075
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Craig V A, Copplestone J A, Hamon M D, Prentice A G. Effect of anti-apolipoprotein 1 on spontaneous apoptosis of B-cells in chronic lymphocytic leukaemia: The role of bcl-2 and interleukin-4. Leukaemia and Lymphoma 1995, in press
   PubMed Web of Science ®Google Scholar
• Larsson L G, Gray H E, Totterman T, Pettersson U, Nilsson K. Drastically increased expression of myc and fos proto-oncogenes during in vitro differentiation of chronic lymphocytic leukaemia cells. Proc. Natl. Acad. Sci. USA 1987; 84: 223–225
   PubMed Web of Science ®Google Scholar
• Galigaris-Cappio F, Gottardi D, Alfarano A, Stacchini A, Gregoretti M G, Ghia P, Bertero M T, Navarino A, Bergui L. The nature of the B lymphocytes in B-chronic lymphocytic leukaemia. Blood Cells 1993; 19: 601–603
   PubMedGoogle Scholar
• Oscier D G. Cytogenetic and molecular abnormality in chronic lymphocytic leukaemia. Blood Rev 1984; 8: 88–97
   Web of Science ®Google Scholar
• Gallard R E. Immunoregulation by interleukin-4 in man. Br. J. Haematol 1991; 78: 293–299
   PubMed Web of Science ®Google Scholar
• Luo H, Rubio M, Biron G, Delespesse G, Sarfati M. Antiproliferative effects of interleukin-4 in B-chronic lymphocytic leukaemia. J. Immunother 1991; 10: 418–425
   PubMed Web of Science ®Google Scholar
• Perri T. Impaired expression of cell surface receptors for B cell growth factor for chronic lymphocytic leukaemia B-cells. Blood 1986; 67: 993–948
   PubMed Web of Science ®Google Scholar
• Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukaemia B-cells from death by apoptosis and upregulates bcl-2 expression. J. Exp. Med 1992; 176: 1319–1326
   PubMed Web of Science ®Google Scholar
• Ojeda F, Guarda M J, Maldonado C, Folch U. Protein kinase-C involvement in thymocyte apoptosis induced by hydrocortisone. Cell Immunol 1990; 125: 535–539
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding S R, Richard C, Hoffbrand A V, Brenner M K. Interferon-y inhibits apoptotic cell death in B-cell chronic lymphocytic leukaemia. J. Exp. Med 1993; 177: 213–218
   PubMed Web of Science ®Google Scholar
• McConkey D J, Hartzell P, Chow S C, Orrenius S, Jondal M. Interleukin 1 inhibits T-cell receptor-mediated apoptosis in immature thymocytes. J. Biol. Chem 1990; 265: 3009–3011
   PubMed Web of Science ®Google Scholar
• Huang R.-W, Tsuda H, Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukaemia cells. Int. J. Hematol 1993; 58: 83–92
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H W.L, Schlag R, Fleiger D, Thiel E. Favorable response of early stage B-CLL patients to treatment with interferon-alpha 2. Blood 1989; 73: 1426–1430
   PubMed Web of Science ®Google Scholar
• Osthund L, Einhorn S, Robert K.-H, Juliusson G, Biberfeld P. Chronic lymphocytic leukaemia cells proliferate and differentiate following exposure to interferon. in vitro. Blood 1986; 67: 152–159
   PubMed Web of Science ®Google Scholar
• Trichineri G, Perussia B. Immune interferons: A pleotropic cytokine with multiple effects. Immunol. Today 1985; 6: 131–136
   PubMedGoogle Scholar
• Totterman T H, Danersund A, Carlsson M, Nilsson K. Effect of recombinant interferon-alpha and gamma on B-cells in serum free medium. Expression of activation, differentiation and CALLA markers. Leukemia 1987; 1: 667–679
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Ganeshaguru K, Jabbar S A. B, Hoffbrand A V. Alpha-interferon (α-INF) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death. in vitro. Br. J. Haematol 1994; 86: 169–173
   PubMed Web of Science ®Google Scholar
• Sanderson C J, Campbell H D, Young I G. Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B-cells. Immunol. Rev 1988; 102: 29–52
   PubMed Web of Science ®Google Scholar
• Clutterbuck E, Shields J G, Gordon J, Smith S H, Boyd A, Gallard R E, Campbell H D, Young I G, Sanderson C J. Recombinant human interleukin-5 is an eosinophil differentiation factor but has no activity in standard human B-cell growth factor assays. Eur. J. Immunol 1987; 17: 1743–1750
   PubMed Web of Science ®Google Scholar
• Bertolini J N, Sanderson C J, Benson E M. Human interleukin 5 induces staphyloccal A cowan 1 strain-activated human B-cells to secrete IgM Eur. J. Immunol 1993; 23: 398–402
   Web of Science ®Google Scholar
• Baumann M A, Paul C C. Interleukin-5 is an autocrine growth factor for Epstein-Barr virus—tranfected B lymphocytes. Blood 1992; 79: 1763–1767
   PubMed Web of Science ®Google Scholar
• Hayes T G, Tan X.-L, Moseley A B, Huston M M, Huston D P. Abnormal response to interleukin-5 in B-cell chronic lymphocytic leukaemia. Leukaemia Res 1993; 17: 777–783
   PubMed Web of Science ®Google Scholar
• Swain S L, Dutton R W. Production of a B-cell growth-promoting activity (DL) BCGF from a cloned T-cell line and its assay on the B-CL1 B-cell tumour. J. Exp. Med 1982; 156: 1821–1834
   PubMed Web of Science ®Google Scholar
• Wetzel G D. Interleukin-5 regulation of peritoneal Ly-1 B lymphocyte proliferation, differentiation and autoantibody secretion. Eur. J. Immunol 1989; 18: 1701–1707
   Web of Science ®Google Scholar
• Hasbold J, Klaus G G. B. Anti-immunoglobuline antibodies induce apoptosis in immature B-cell lymphomas. Eur. J. Immunol 1990; 20: 1685–1690
   PubMed Web of Science ®Google Scholar
• Larrick J W, Wright S C. Cytotoxic mechanism of tumour necrosis factor-α. FASEB J 1990; 4: 3215–3223
   PubMed Web of Science ®Google Scholar
• Kizaki H, Nakada S, Ohnishi Y, Azuma Y, Mizuno Y, Tada Kuma T. Tumour necrosis factor-alpha enhances cAMP-induced programmed cell death in mouse thymocytes. Cytokine 1993; 5: 342–347
   PubMed Web of Science ®Google Scholar
• Gotlieb W H, Watson J M, Rezai A, Johnson M, Martinez-Maza O, Berek J S. Cytokine-induced modulation of tumour suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumour necrosis factor-alpha. Am. J. Obstet. Gynecol 1994; 170: 1121–1128
   PubMed Web of Science ®Google Scholar
• Wright S C, Zheng H, Zhong J, Torti F M, Larrick J W. Role of protein phorphorylation in tumour necrosis factor-induced apoptosis: Phosphatase inhibitors synergise with tumour necrosis factor to activate DNA fragmentation in normal as well as tumour-necrosis factor-resistant U937 variants. J. Cell. Biochem 1993; 53: 222–223
   PubMed Web of Science ®Google Scholar
• Dhein J, Daniel P T, Trauth B C, Oehm A, Moller P, Krammer P H. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol 1992; 149: 3166–3173
   PubMed Web of Science ®Google Scholar
• Owen-Schanb L B, Yonehara S, Crump I II W. L., Grimm E A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by FAS antigen engagement. Cell. Immunol 1992; 190: 197–205
   Web of Science ®Google Scholar
• Debatin K.-M, Goldman C K, Waldmann T A, Krammer P H. APO-1-induced apoptosis of leukaemia cells from patients with adult T cell leukaemia. Blood 1993; 81: 2972–2977
   PubMed Web of Science ®Google Scholar
• Mapara M Y, Bargon R, Zugock C, Dohner H, Ustaoglu F, Jonker R R, Krammer P H, Dorken B. APO-1 mediated apoptosis on proliferation in human chronic B lymphocytic leukaemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol 1993; 23: 702–708
   PubMed Web of Science ®Google Scholar
• McConkey D J, Hartzell P, Jondal M, Orrenius S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J. Biol. Chem 1989; 264: 13399–13402
   PubMed Web of Science ®Google Scholar
• Migliorati G, Pagliacci M D, D'Adamio F, Crocicchio F, Nicoletti I, Riccardi C. Glucocorticoid-induced DNA fragmentation: role of protein kinase-C activity. Pharmacol. Res 1992; 26: 5–9
   PubMedGoogle Scholar
• Hickman J A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121–139
   PubMed Web of Science ®Google Scholar
• McConkey D J, Orrenius S, Jondal M. Cellular signalling in programmed cell death apoptosis. Immunol. Today 1990; 11: 120–121
   PubMedGoogle Scholar
• Craig V A, Mainou-Fowler T, Prentice A G. Effect of interleukin-4 (IL4) and dexamethasone and bcl-2 expression in B-chronic lymphocytic leukaemia (B-CLL) in culture. Exp. Hematol 1993; 21: 1090, (abstr)
   Web of Science ®Google Scholar
• Jewell A P, Worman C P, Lydyard P M, Young K L, Giles F J, Goldstone A H. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br. J. Haematol 1994; 88: 268–274
   PubMed Web of Science ®Google Scholar
• Tagam T, Kishimoto T. Cytokine receptors and signal transduction. FASER, J 1993; 6: 3387–3396
   Web of Science ®Google Scholar
• Boise L H, Gonzalez-Garcia M, Postema C E, Ding L, Lindsten T, Turka L A, Mao X, Nunez G, Thompson C B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–606
   PubMed Web of Science ®Google Scholar
• Oltvai Z H, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Yin X M, Oltvai Z N, Korsmeyer S J. BH1 and BH2 domains of bcl-2 are reguired for inhibition of apoptosis and heterodimerisation with Bax. Nature 1994; 369: 321–23
   PubMed Web of Science ®Google Scholar
• Lewis D B, Prickett K S, Larsen A, Grerbstein K, Weaver M, Wilson C B. Restricted production of interleukin-4 by activated human T-cells. Proc. Natl Acad. Sci. USA 1988; 85: 9743–9748
   PubMed Web of Science ®Google Scholar
• Sewell W A, Valentin J E, Cooley M A. Expression of interleukin-5 by CD4+ CD45RO+ subset of T-cells. Growth Factors 1992; 6: 295–302
   PubMed Web of Science ®Google Scholar
• Totterman T H, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-celi activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989; 74: 786–92
   PubMed Web of Science ®Google Scholar
• Antica M, Kusic B, Spaventi R, Jaksic B, Vitale B. Functional differences of T cells in B-chronic lymphocytic leukaemia. Leukaemia and Lymphoma 1993; 9: 133–140
   PubMed Web of Science ®Google Scholar